Cefazolin injection reduces the rate of postoperative endophthalmitis

Article

Administering cezafolin injections after cataract surgery reduces the rate of postoperative endophthalmitis.

Administering cefazolin injections after cataract surgery reduces the rate of postoperative endophthalmitis, claims a study in the journal Bio Med Central.

Dr Pedro Romero-Aroca et al., Ophthalmology Service. Hospital Universitari Sant Joan, IISPV, Universidad Rovira i Virgili, Reus, Spain, conducted a prospective, observational study on 25001 patients.

All participants were divided into two groups: Group 1, consisting of 11696 patients, was operated on between January 2002 and December 2002 and Group 2, with 13305 patients, was administered a 1 mg/0.1 bolus of intracameral cefazolin between January 2003 and December 2009.

Of the patients studied, there were 76 cases of endophthalmitis in Group 1, compared to 7 in Group 2. Postoperative endophthalmitis rate decreased from 0.63% to 0.05% after a cefazolin. The relative risk of endophthalmitis in Group 1, compared to Group 2, was 11.45.

Intracameral bolus injections of cefazolin after cataract surgery significantly reduce the rate of postoperative endophthalmitis.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.